Lieping Chen

DrChenSmallProfessor of Immunobiology, Dermatology and Medicine and Director of Cancer Immunology Programme
Yale University School of Medicine, USA

Dr Lieping Chen is currently United Technologies Corporation Endowed Chair in Cancer Research, Professor of Immunobiology, Dermatology and Medicine (Medical Oncology) and Director of Cancer Immunology Programme in Yale University School of Medicine, USA.

Dr Chen studies lymphocyte costimulation and coinhibition and their application in treating human diseases.  In 1992, his works built original concept for current efforts using costimulatory and coinhibitory molecules to enhance tumour immunity as an approach to treat human cancer.  Dr Chen co-discovered the PD-1/PD-L1 pathway and singularly established the PD-1/PD-L1 pathway as cancer therapy target.  He also help to initiate and organise the first-in-man clinical trial of anti-PD-1 antibody for treating human cancer and developed PD-L1 staining as a biomarker to predict treatment outcome.  Dr Chen’s discoveries have revolutionized cancer treatment and led to the development of anti-PD-1/PD-L1 antibody therapy against broad spectrum of advanced human cancers (FDA approved drugs in 2014). His laboratory also discovered many important immune modulation pathways (4-1BB, ICOS/B7-H2, B7-H3, B7-H4, B7-H5/CD28H, PD-1H, LIGHT/HVEM, TROY), their immunological functions and applications in human disease treatment. Their findings result in the development of therapeutic agents including agonist anti-4-1BB (CD137) antibodies (cancer), anti-B7-H3 antibodies (cancer) and B7-H4Ig fusion protein (autoimmune diseases) which are currently in clinical trials.

Dr Chen has published more than 300 papers, reviews, book chapters and edited two books. His work in discovery of the PD-1/PD-L1 pathway in cancer therapy was cited as the number 1 breakthrough of the years by Science magazine (2013). He has received several awards and professional recognitions including William B. Coley Award (2014) and AAI-Steinman Award (2016).